Habek, M., Drulović, J., Brecl Jakob, G., Barbov, I., Radulovic, Lj., Rajda, C. ... Turčáni, P. (2022). Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy, 12. (1), 25-37. doi: 10.1007/s40120-022-00422-z
Habek, Mario, et al. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy, vol. 12, br. 1, 2022, str. 25-37. https://doi.org/10.1007/s40120-022-00422-z
Habek, Mario, Jelena Drulović, Gregor Brecl Jakob, Ivan Barbov, Ljiljana Radulovic, Cecilia Rajda, Konrad Rejdak i Peter Turčáni. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy 12, br. 1 (2022): 25-37. https://doi.org/10.1007/s40120-022-00422-z
Habek, M., et al. (2022) 'Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers', Neurology and Therapy, 12(1), str. 25-37. doi: 10.1007/s40120-022-00422-z
Habek M, Drulović J, Brecl Jakob G, Barbov I, Radulovic Lj, Rajda C, i sur.. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy [Internet]. 17.11.2022. [pristupljeno 07.10.2024.];12(1):25-37. doi: 10.1007/s40120-022-00422-z
M. Habek, et al., "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers", Neurology and Therapy, vol. 12, br. 1, str. 25-37, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:261927. [Citirano: 07.10.2024.]